The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.g

Pulmonary fibrosis

Publications

Janeiro Pais JM, Casas Agudo VP, López Garcia D, González Dacal J, Lamas Meilán C, González Martín M

[Pulmonary fibrosis and endovesical mitomycin C].

Actas urologicas espanolas 2009 Jul-Aug;33;822-5 — 2009 Jul-Aug — 822-5

Okuno SH, Frytak S

Mitomycin lung toxicity. Acute and chronic phases.

American journal of clinical oncology 1997 Jun;20;282-4 — 1997 Jun — 282-4

Fielding JW, Crocker J, Stockley RA, Brookes VS

Interstitial fibrosis in a patient treated with 5-fluorouracil and mitomycin C.

British medical journal 1979 Sep 01;2;551-2 — 1979 Sep 01 — 551-2